47 unknown, 32 completed, 21 recruiting, 16 not yet recruiting. 95 Phase 2, 29 Phase 3, 14 Phase 1, 5 Not applicable, 3 Phase 4.
Follow nimotuzumab: new trials by email Literature Review of nimotuzumab trials Research Report on nimotuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab - Head & Neck Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Ke Hu | 46 | 2026-09-10 | 2026-09-15 |
| A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer HRS-2329 Tablet, Nimotuzumab, HS-20093 - Pancreatic Cancer, RAS Mutations or Amplifications | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 80 | 2026-08-15 | 2026-08-31 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma Toripalimab combined with Nimotuzumab, Nimotuzumab - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 566 | 2026-07-20 | 2026-07-16 |
| Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma nimotuzumab, Temozolomide, Radiotherapy - Glioma, Malignant | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 50 | 2026-07-03 | 2026-07-16 |
| Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma Nimotuzumab, Nimotuzumab, Benmelstobart, Postoperative Radiotherapy - Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 386 | 2026-05-05 | 2026-04-30 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC HLX10, Chemotherapy, Nimotuzumab - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2026-03-12 | 2026-03-11 |
| Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Bemcentinib, Nimotuzumab, radiotherapy - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 370 | 2026-03-04 | 2026-04-17 |
| Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II Sintilimab combined with chemotherapy and nimotuzumab - Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN) | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 23 | 2026-01-10 | 2025-12-30 |
| Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab, intensity-modulated technique（IMRT） - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 335 | 2026-01-05 | 2026-01-12 |
| A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Drug Combination Therapy - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-01-01 | 2026-01-21 |
| Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Nimotuzumab, AG regimen, Placebo - Pancreatic Cancer, Adult | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 156 | 2025-12-10 | 2025-12-11 |
| Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer Nimotuzumab, Toripalimab, Nab-paclitaxel - Head & Neck Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 10 | 2025-11-15 | 2026-01-20 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma Nimotuzumab, camrelizumab, Albumin paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking University | 48 | 2025-11-01 | 2025-12-31 |
| An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer Nimotuzumab and Radiotherapy - Bladder (Urothelial, Transitional Cell) Cancer | Phase 1 | Not yet recruiting | Peking University First Hospital | 30 | 2025-06-30 | 2025-07-08 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma Toripalimab, Nimotuzumab, surgery - Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 70 | 2025-05-16 | 2025-05-21 |
| AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer AG regimen, Nimotuzumab - Pancreatic Cancer, Adult | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 48 | 2025-04-21 | 2025-04-22 |
| HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel - Metastatic Pancreatic Carcinoma | Phase 2 | Recruiting | Zhejiang University | 133 | 2025-03-25 | 2026-06-03 |
| HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma HRS-4642, Nimotuzumab - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 20 | 2025-02-10 | 2026-05-28 |
Showing 20 of 137. Sign in to see all of them.
Nasopharyngeal Carcinoma (19) · Esophageal Neoplasms (12) · Esophageal Squamous Cell Carcinoma (11) · Squamous Cell Carcinoma of Head and Neck (11) · Head and Neck Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Pancreatic Neoplasms (9) · Uterine Cervical Neoplasms (9) · Stomach Neoplasms (4) · Colorectal Neoplasms (3) · Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Diffuse Intrinsic Pontine Glioma (2) · Glioma (2)
Biotech Pharmaceutical Co., Ltd. (20) · Sun Yat-sen University (12) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Peking University (7) · Tianjin Medical University Cancer Institute and Hospital (7) · Chinese Academy of Medical Sciences (6) · Fudan University (5) · YM BioSciences (5) · Zhejiang University (5) · Eurofarma Laboratorios S.A. (4) · Oncoscience AG (3) · Peking University Third Hospital (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Air Force Military Medical University, China (2) · Fujian Cancer Hospital (2)
China (101) · Canada (6) · South Korea (5) · Brazil (4) · United States (4) · Cuba (3) · Germany (3) · Singapore (3) · Taiwan (2) · Algeria (1) · Australia (1) · Egypt (1) · India (1) · Indonesia (1) · Israel (1)
Jihui Hao, Dr (3) · He Xiaohui (2) · Lin Shen (2) · Qiong Zhao, MD (2) · Zi Liu (2) · Algemir L Brunetto (1) · Amil Shah, MD (1) · Anthony Brade, M.D. (1) · Anthony Brade, MD (1) · Binghe Xu (1) · Chenping Zhang (1) · Chong Zhao, MD (1) · Chunyi Hao (1) · Claudia T Oliveira (1)
PMID 10655437, PMID 11937316, PMID 12177103, PMID 12434281, PMID 14506149, PMID 14967459, PMID 16011702, PMID 16078267, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 17544337, PMID 17647306, PMID 17909941, PMID 18217208, PMID 18577561, PMID 18990510, PMID 19147777, PMID 19957326, PMID 19985059, PMID 20694800, PMID 20708924, PMID 20921456, PMID 20974795, PMID 21087935, PMID 21171927, PMID 21292687, PMID 21297126, PMID 21297433, PMID 21327862, PMID 21462364, PMID 21684205, PMID 22132908, PMID 22331797, PMID 22555809, PMID 22646630, PMID 22747087, PMID 22747092, PMID 23043252, PMID 23092726, PMID 23536435, PMID 23813229, PMID 24115004, PMID 24560760, PMID 24626721, PMID 24696052, PMID 24847085, PMID 24903904, PMID 25542058
2015 (1)